Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
630 stopped studies mapped to Malignant Hepatobiliary Neoplasm and descendants · 92% state a reason
Over the 630 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01862718 | Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms | Phase 1 | terminated | May 24, 2013 | National Institutes of Health Clinical Center (CC) | Slow/Insufficient accrual | Enrollment / accrual |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic… | Phase 1 | terminated | Feb 2, 2012 | Washington University School of Medicine | Equipment that was used in the study was discontinued | Other (stated, no rule matched) |
| NCT04775056 | A Study to Evaluate Vaccines Against COVID-19 in the Real World | — | withdrawn | Mar 1, 2021 | Humanity & Health Medical Group Limited | No sponsor | Other (stated, no rule matched) |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | N/A | terminated | May 18, 2015 | Wright State University | Insufficient number of subjects meeting inclusion criteria | Other (stated, no rule matched) |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Oct 14, 2015 | Kathy Miller | Funder Decision | Other (stated, no rule matched) |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | Phase 2 | terminated | Sep 4, 2008 | BTG International Inc. | Study terminated prematurely by sponsor for business reason. One patient was enrolled. | Enrollment / accrual |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating…(HOPE) | N/A | withdrawn | Jan 22, 2021 | Poitiers University Hospital | No enrollment | Enrollment / accrual |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | N/A | terminated | Jan 18, 2018 | Duke University | Lack of enrollment | Enrollment / accrual |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Lion TCR Pte. Ltd. | Major changes in manufacturing process and investigational product | Drug supply |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase 2 | withdrawn | May 20, 2021 | Walid Shaib, MD | Funder decision | Other (stated, no rule matched) |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC…(PATRON) | Phase 3 | terminated | Jul 26, 2011 | Cellxpert Biotechnology Corp. | Due to Interim Analysis and business concerns | Efficacy / futility |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | N/A | terminated | May 21, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | Change of the scientific and medical context that is no longer favorable to our study. This has… | Other (stated, no rule matched) |
| NCT03110510 | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were… | Phase 2 | withdrawn | Apr 12, 2017 | Samsung Medical Center | institution problem | Other (stated, no rule matched) |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy… | Phase 2 | withdrawn | Sep 14, 2020 | Samsung Medical Center | problem of sponsor | Other (stated, no rule matched) |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | — | withdrawn | Dec 9, 2019 | University Hospital, Grenoble | the possibility of obtaining histological data is too low due to the lack of availability of… | Other (stated, no rule matched) |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | Phase 2 | terminated | Jan 27, 2021 | AIO-Studien-gGmbH | Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine… | Enrollment / accrual |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced… | Phase 1 | terminated | Feb 23, 2017 | SignalRX Pharmaceuticals, Inc. | Lack of recruitment and sponsor's priority changes | Enrollment / accrual |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04… | Phase 3 | withdrawn | Jul 10, 2020 | Shanghai Henlius Biotech | The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been… | Other (stated, no rule matched) |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | N/A | terminated | Mar 9, 2016 | Wake Forest University Health Sciences | Lack of funding | Funding |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | Phase 1 | withdrawn | Jul 21, 2020 | Jordan Kharofa | Difficulty accruing | Enrollment / accrual |
| NCT03396705 | Liver Regeneration | — | terminated | Jan 11, 2018 | University Health Network, Toronto | Poor recruitment | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment… | Phase 2 | withdrawn | Aug 25, 2021 | Fudan University | Repeat registration | Other (stated, no rule matched) |
| NCT04231929 | BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre…(BIOPEARL-FIRST) | N/A | withdrawn | Jan 18, 2020 | Terumo Europe N.V. | Study cancelled by Sponsor decision | Sponsor / business decision |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | N/A | terminated | Jun 7, 2019 | Milton S. Hershey Medical Center | Recruitment challenges | Enrollment / accrual |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Phase 2 | terminated | Dec 1, 2020 | American University of Beirut Medical Center | pharma company decision to withdraw the financial and IMP support | Funding |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab… | Phase 2 | terminated | Dec 5, 2016 | Aiwu Ruth He, MD | Manufacturer discontinued Sylatron | Drug supply |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | Phase 1 | suspended | Aug 10, 2020 | Beijing Tsinghua Chang Gung Hospital | Adjust the plan | Other (stated, no rule matched) |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | Phase 2 | withdrawn | Apr 9, 2019 | Louisiana State University Health Sciences Center in New Orleans | Dr. Marshall left UMC and LSU Health Sciences Center. | Other (stated, no rule matched) |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | Phase 2 | terminated | Dec 4, 2020 | Zhejiang University | The treatment efficacy was not satisfactory. | Efficacy / futility |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | Phase 2 | terminated | Jul 20, 2020 | SC Liver Research Consortium, LLC | Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity… | Safety / toxicity |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | Phase 1 / Phase 2 | withdrawn | Sep 26, 2019 | Washington University School of Medicine | One of the investigators is leaving the University. | Other (stated, no rule matched) |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of…(HiQuality) | Phase 3 | terminated | Jul 6, 2011 | Merit Medical Systems, Inc. | The clinical study was terminated due to the inability to meet target enrollment. | Enrollment / accrual |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic… | Phase 1 / Phase 2 | terminated | Mar 6, 2017 | Transgene | The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab… | Other (stated, no rule matched) |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in…(DESPARTH) | Phase 1 | terminated | Dec 1, 2014 | University Hospital, Ghent | slow recruitment of patients | Enrollment / accrual |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San…(HCC) | N/A | terminated | Jun 10, 2010 | Loma Linda University | due to low enrollment | Enrollment / accrual |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | N/A | withdrawn | Aug 13, 2020 | Michael Lidsky, M.D. | No subjects enrolled due to availability of device commercially. | Enrollment / accrual |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | Phase 2 | withdrawn | Jul 1, 2021 | Shanghai Zhongshan Hospital | The standard of care of adjuvant therapy for liver cancer was changed. | Other (stated, no rule matched) |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic… | Phase 2 | withdrawn | Jul 21, 2020 | Jiangsu HengRui Medicine Co., Ltd. | It is difficult to screening subject | Other (stated, no rule matched) |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | Phase 1 | terminated | Jun 29, 2017 | University of Chicago | Study stopped due to poor accrual. | Enrollment / accrual |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | Phase 2 | terminated | Dec 16, 2009 | New Mexico Cancer Research Alliance | Low accrual rate | Enrollment / accrual |
| NCT02893982 | High Dose Rate Brachyablation of Primary Liver Lesions | Phase 1 | terminated | Sep 9, 2016 | University of Texas Southwestern Medical Center | Study was closed due to poor accrual | Enrollment / accrual |
| NCT02721056 | NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment… | Phase 1 / Phase 2 | terminated | Mar 28, 2016 | Nanobiotix | The RP2D for intratumoral injection was determined. With the changing practice of medicine for HCC,… | Other (stated, no rule matched) |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With… | Phase 2 | terminated | Aug 1, 2018 | Chang Gung Memorial Hospital | The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 15, 2022source: clinicaltrials